Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 10/24 01:23:10 pm
16.15 EUR   -0.65%
10/23 ABLYNX : 23/10/2017 ablynx announces warrant exercise
10/23 ABLYNX : Announces warrant exercise
10/23 ABLYNX : Announces warrant exercise
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
10/23ABLYNX ANNOUNCES WARRANT EXERCISE  
10/23Ablynx : ANNOUNCES WARRANT EXERCISE  
10/21Ablynx NV $ABLX to Raise $151 Million in IPO  
10/20$ABLYF - Zacks: Ablynx N.V. #ABLYF Receives Average Rating of "Strong Buy" fr.. 
10/17Ablynx prices $175M U.S. IPO at $20.95  
10/17#IPOs ? Belgian biotech Ablynx sets terms for $175 million global IPO $ABLX $.. 
10/17ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
10/17Ablynx : 17/10/2017 ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
10/17Ablynx : ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING  
10/16In wake of ph 3 aTTP data, US #IPO filing, Ablynx on the move with establishm.. 
10/16So is Ablynx's caplacizumab a wink and nod to Klingon (capla/Qapla') for "suc.. 
10/16BRIEF-Ablynx establishes subsidiary in USA  
10/16ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER  
10/16Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY.. 
10/16Ablynx : ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER  
10/08Zacks: Ablynx N.V. $ABLYF Receives Consensus Rating of “Strong Buy” from Brok.. 
10/06Ablynx N.V. $ABLYF Stock Rating Lowered by Zacks Investment Research  
10/05#IPOs ? Belgian biotech Ablynx files for a $150 million IPO $ABLX $IPO #IPO  
10/05Zacks Investment Research Lowers Ablynx N.V. $ABLYF to Sell  
10/05EuroBiotech Report—Ablynx’s big week, Amgen backs Immatics, Motif Bio phase 3..
2
10/03VC-backed Ablynx files for IPO
1
10/03Ablynx files for $150M IPO to build on phase 3 boost:
4
10/03Ablynx se tourne vers le Nasdaq  
10/03Ablynx N.V. downgraded by Zacks Investment Research to sell.  
10/03ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING  
10/03#IPOs ? Belgium biotech Ablynx files for a $150 million IPO $ABLX $IPO #IPO  
10/02Ablynx: ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING #f.. 
10/02Ablynx's caplacizumab successful in late-stage study in rare blood disorder; .. 
10/02Ablynx scores with blood clot drug  
10/02Ablynx’s caplacizumab hits primary endpoint in phase 3  
10/02Ablynx spikes as PhIII aTTP study comes through with promising data, setting ..
5
10/02Belgian biotech Ablynx scores big hit with blood disease drug
4
10/02Ablynx : Belgian biotech Ablynx scores big hit with blood disease drug  
10/02ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY O.. 
09/27Ablynx N.V. $ABLYF Downgraded to Sell at Zacks Investment Research  
09/27Ablynx N.V. downgraded by Zacks Investment Research to sell.  
09/19Briefing 19/9 Solvay, Proximus, Umicore, Ageas, Ontex, IBA, Nyrstar, Kinepoli.. 
09/19Briefing 19/9 Solvay, Proximus, Umicore, Ageas, Ontex, IBA, Nyrstar, Kinepoli.. 
09/19Ablynx N.V. upgraded by Zacks Investment Research to hold.  
09/14ABLYNX ANNOUNCES WARRANT EXERCISE  
09/11Ablynx N.V. $ABLYF Cut to “Sell” at Zacks Investment Research  
09/11$ABLYF - Ablynx N.V. #ABLYF Cut to "Sell" at Zacks Investment Research  
09/09$ABLYF - Ablynx N.V. #ABLYF Lowered to Sell at Zacks Investment Research  
09/09Ablynx N.V. downgraded by Zacks Investment Research to sell.  
09/07ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON  
09/07Ablynx : TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON  
08/24Ablynx NV reports 1H results  
08/24ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE  
08/24Ablynx : ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE  
08/17ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 201.. 
More tweets
Qtime:40
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 16,8x
EV / Sales 2018 18,1x
Capitalization 998 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX50.30%1 173
INCYTE CORPORATION13.17%23 905
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP57.01%19 531
CELLTRION, INC.--.--%19 395
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522